Boston Oncology CGT Holding

Boston Oncology CGT Holding is a specialized biopharmaceutical company focused on the development and localized manufacturing of cell and gene therapies (CGT) in the Middle East and North Africa (MENA) region. As a key subsidiary of Boston Oncology, the entity aims to establish a robust regional value chain for advanced therapeutics, including CAR-T cell therapies and other regenerative medicines. The company utilizes a strategic technology transfer model, partnering with global innovators to license and produce high-quality, affordable versions of complex biologics. Operating with a hub-and-spoke approach, it combines research and development expertise from its Boston-based headquarters with large-scale, GMP-certified production at its facilities in Saudi Arabia. Boston Oncology CGT Holding is a central player in regional healthcare initiatives like Saudi Arabia's National Biotechnology Strategy, which seeks to localize 40% of the pharmaceutical market. By bridging the gap between international biotech innovation and local patient access, the company works to improve outcomes for oncology and hematology patients across the region.